✩ 本文仅供医疗卫生等专业人士参考
审批码：HS-NP-A107-2609-01918
本资料仅供中国境内医疗卫生专业人士参阅，旨在分享研发前沿资讯，非推广用途，不应被理解为对特定药物的推荐或者建议。请勿参考或倚赖本平台下的任何内容，有关疾病或药品的相关问题，请咨询有资质的医疗专业人员
内容策划：方程
项目审核：李淳
题图来源：丁香园设计
参考文献
[1] J Wang, et al. Risvutatug Rezetecan (a B7-H3-Directed ADC) Versus Topotecan in Relapsed SCLC: Primary Results of Phase 3 ARTEMIS-008. 2026 WCLC. PL02.04.
[2] Lu Y, Fan Y. Research Progression of Maintenance Therapy in Small Cell Lung Cancer[J]. Zhongguo Fei Ai Za Zhi. 2015 Sep 20;18(9):559-64.
[3] Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer.
[4] Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncology. 2020;21(9):1224-1233.
[5] Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.New England journal of Medicine. 2025;393:349-361.
[6] Carvajal-Hausdorf D, Altan M, Velcheti V, et al. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung cancer (SCLC). J Immunother Cancer. 2019;7(1):65.
[7] Campisi M, Stornante C, Dryg ID, et al. Targeting B7-H3 in the small cell lung carcinoma tumor-immune microenvironment. Cancer Res. 2026;86(7 Suppl):Abstract 5603.
[8] Zhou WT, Jin WL. B7-H3/CD276: an emerging cancer immunotherapy. Front Immunol. 2021;12:701006.
[9] World Health Organization. Rezetecanum. In: International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN List 127. WHO Drug Information. 2022;36(2).
[10] Waight J, Zhou Y, Sun D, et al. Abstract 7097: Non-clinical characterization of GSK5764227, a novel B7-H3-directed antibody-drug conjugate (ADC). Cancer Res. 2026;86(7 Suppl):7097. doi:10.1158/1538-7445.AM2026-7097.
[11] Duan J, Sun Y, Wang Q, et al. HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: results from the ARTEMIS-001 phase 1a/b trial. Cancer Cell. 2026;44(4):846-857.e3.
[12] Zhong H, et al. CT038-Combination of risvutatug rezetecan and adebrelimab in previously treated advanced nsq-NSCLC without actionable genomic alterations: Results from ARTEMIS-101, a phase 1 study.2026 AACR.
[13] ClinicalTrials.gov. Study NCT07464327. https://clinicaltrials.gov/study/NCT07464327.
热门跟贴